Loading institutional data...
Loading institutional data...
No institutional (13F) filings cover this company, so the Overview and 13F tabs are thin. Everything drawn from its SEC filings is here.
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Solve the discounted cash flow backwards, then stress-test the assumptions.
Average free cash flow across the last 2 positive fiscal years (FY2023, FY2025). Smooths the cycle. Stock compensation is NOT charged — it is added back inside operating cash flow.
To be worth $0.15 today, the market must believe free cash flow compounds -32.3%/yr for a decade (off $348K on the 3-yr avg basis).
The market's -32.3% is more conservative than its 4-yr track record.
Default is 11.2% — this company's computed cost of capital (computed WACC), the same rate the Analysis tab discounts at.
2-stage DCF · 0.01B shares (market data) · net debt -$546K
Today's price is outside this grid at every discount rate shown — the assumptions it requires lie beyond the plotted range, which is itself the finding.
mean -264.3% · volatility σ 53% · implied rate exceeded in 0/2 yrs
Central path = implied -32.3%/yr growth; shaded band = ±1σ (53%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Ranked against 13 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-06-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MDT | $113.2B | 23.7× | 14.8× | 3.1× | 8.4% | 65.0% | 13.2% | 9.7% | 6.2% | 2.8× | 2,050 |
| ITGR | $4.3B | 43.8× | 15.6× | 2.3× | 8.0% | 27.0% | 5.5% | 5.9% | 3.5% | 3.3× | 309 |
| LIVN | $4.2B | — | 17.3× | 3.0× | 10.7% | 67.7% | -17.5% | -20.2% | -15.4% | -1.1× | 294 |
| TMDX | $2.7B | 16.0× | 16.4× | 4.5× | 37.1% | 59.9% | 31.4% | 40.2% | 39.4% | -3.5× | 371 |
| AXGN | $2.1B | — | — | 9.4× | 20.2% | 74.3% | -7.0% | -12.2% | -8.9% | — | 241 |
| BLFS | $1.9B | — | — | 19.6× | 28.9% | 64.6% | -4.8% | -1.2% | -1.2% | — | 207 |
| CNMD | $1.3B | 29.4× | 18.1× | 1.0× | 5.2% | 54.6% | 3.4% | 4.6% | 2.5% | 7.0× | 236 |
| CBLL | $907M | — | — | 10.2× | 36.1% | 87.9% | -60.0% | -34.4% | -34.4% | — | 123 |
| INMD | $818M | 9.9× | 6.0× | 2.2× | -6.2% | 78.5% | 25.3% | 13.7% | 13.7% | -3.5× | 185 |
| CV | $351M | — | — | 25.9× | 15.3% | 52.9% | -187% | -191% | -191% | — | 51 |
| ELMD | $229M | 21.3× | 14.2× | 3.1× | 15.3% | 78.5% | 15.3% | 20.9% | 20.9% | -1.4× | 128 |
| FOCL | $198M | — | — | 2.8× | 1.6% | 42.5% | -41.5% | -151% | -73.7% | — | — |
| STXS | $111M | — | — | 3.4× | 20.3% | 52.7% | -66.8% | -161% | -161% | — | 108 |
| ESMC | $1M | — | 3.3× | 0.1× | 0.5% | 45.7% | 0.9% | 5.5% | 5.5% | -3.2× | — |
Peers = companies sharing ESMC's sector (Electromedical & Electrotherapeutic Apparatus) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $377K FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 6%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
EOD close · as of 2026-10-09
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.0M 100.0% | $12.0M 100.0% | $12.2M 100.0% | $10.7M 100.0% | $10.5M 100.0% | $9.4M 100.0% | $9.6M 100.0% | $11.4M 100.0% | $11.2M 100.0% | $11.6M 100.0% |
| Cost of Revenue | $6.5M 54.3% | $6.8M 57.0% | $6.7M 55.0% | $6.1M 57.0% | $6.0M 57.7% | $5.2M 55.3% | $5.0M 51.9% | $6.3M 55.2% | $6.1M 54.1% | $6.2M 53.5% |
| Cost of Products | — | — | — | — | — | — | — | $6.3M 55.2% | $6.1M 54.1% | $6.2M 53.5% |
| Research & Development | $753K 6.3% | $688K 5.7% | $819K 6.7% | $991K 9.3% | $890K 8.5% | $1.1M 11.9% | $740K 7.7% | $500K 4.4% | $1.1M 9.4% | $1.5M 12.5% |
| Selling, General & Admin | $4.6M 38.4% | $4.6M 38.1% | $4.2M 34.4% | $4.1M 38.2% | $3.6M 34.1% | $3.9M 41.2% | $4.1M 43.0% | $4.4M 38.6% | $4.6M 41.0% | $5.1M 43.8% |
| Total Operating Expenses | $11.9M 98.9% | $12.1M 100.9% | $11.7M 96.1% | $11.2M 104.4% | $10.5M 100.3% | $10.8M 114.9% | $9.9M 102.6% | $11.2M 98.2% | $11.9M 105.6% | $12.7M 109.9% |
| Operating Income | $133K 1.1% | -$104K -0.9% | $479K 3.9% | -$470K -4.4% | -$34K -0.3% | -$1.4M -14.9% | -$253K -2.6% | $205K 1.8% | -$627K -5.6% | -$1.1M -9.9% |
| Interest Expense | $23K 0.2% | $21K 0.2% | $22K 0.2% | $18K 0.2% | $22K 0.2% | $14K 0.1% | $17K 0.2% | $126K 1.1% | $100K 0.9% | $11K 0.1% |
| Interest & Investment Income | — | — | $128 0.0% | $245 0.0% | $985 0.0% | $4K 0.0% | $9K 0.1% | $5K 0.0% | $327 0.0% | $179 0.0% |
| Other Income (Expense), net | -$28K -0.2% | -$21K -0.2% | -$22K -0.2% | $488K 4.6% | -$18K -0.2% | $749K 8.0% | $3K 0.0% | $379K 3.3% | -$100K -0.9% | -$11K -0.1% |
| Income Tax Expense | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | — | — | — | — | — | — |
| Net Income | $106K 0.9% | -$125K -1.0% | $457K 3.8% | $18K 0.2% | -$52K -0.5% | -$650K -6.9% | -$250K -2.6% | $584K 5.1% | -$727K -6.5% | -$1.2M -9.9% |
| Per Share | ||||||||||
| EPS (Basic) | $0.00 | -$0.02 | $0.03 | $0.00 | -$0.01 | -$0.09 | -$0.04 | $0.07 | -$0.10 | -$0.15 |
| EPS (Diluted) | $0.00 | -$0.02 | $0.03 | $0.00 | -$0.01 | -$0.09 | -$0.04 | $0.06 | -$0.10 | -$0.15 |
| Weighted Avg Shares (Basic) | 7.4M | 7.4M | 7.4M | 7.4M | 7.4M | 7.4M | 7.4M | 7.6M | 7.6M | 7.5M |
| Weighted Avg Shares (Diluted) | 14.3M | 7.4M | 13.6M | 13.2M | 7.4M | 7.4M | 7.4M | 9.1M | 7.6M | 7.5M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
EOD close · as of 2026-10-09
Where each multiple sits in its own 14-yr range · 15th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
ROE 6% against ROIC 6% — 0% of the return on equity comes from leverage and buybacks rather than from the operating business.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 55.2 | 51.9 | 55.3 | 57.7 | 57.0 | 55.0 | 57.0 | 54.3 |
| R&D | 4.4 | 7.7 | 11.9 | 8.5 | 9.3 | 6.7 | 5.7 | 6.3 |
| SG&A | 38.6 | 43.0 | 41.2 | 34.1 | 38.2 | 34.4 | 38.1 | 38.4 |
| Operating Income | 1.8 | -2.6 | -14.9 | -0.3 | -4.4 | 3.9 | -0.9 | 1.1 |
| Income Tax | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | 5.1 | -2.6 | -6.9 | -0.5 | 0.2 | 3.8 | -1.0 | 0.9 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on ESMC: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
How much the company owes, how it's trended, and how comfortably it's serviced.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Coverage is adequate but not comfortable.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
Cost of capital cannot be computed, so the spread is unknown.
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2016 | 46.5% | -9.9% | -9.9% |
| FY2017 | 45.9% | -5.6% | -6.5% |
| FY2018 | 44.8% | 1.8% | 5.1% |
| FY2019 | 48.1% | -2.6% | -2.6% |
| FY2020 | 44.7% | -14.9% | -6.9% |
| FY2021 | 42.3% | -0.3% | -0.5% |
| FY2022 | 43.0% | -4.4% | 0.2% |
| FY2023 | 45.0% | 3.9% | 3.8% |
| FY2024 | 43.0% | -0.9% | -1.0% |
| FY2025 | 45.7% | 1.1% | 0.9% |
Return on equity (6%) and return on invested capital (6%) are within a couple of points in FY2025, so the headline return is the operating return — there is no meaningful leverage effect to strip out.
No material counter-signal in the checked set: ROIC vs WACC spread, 5-year spread history, gross margin trend, operating margin trend, net margin against 3 years ago, revenue growth, ROIC ex-goodwill gap.
Missing from our data, so excluded from this answer: tax_rate.
Cash conversion of -17.93x sits below the level that would make the earnings clearly cash-backed.
Only 3 profitable years available, so the average is shorter than the five the threshold assumes.
Missing from our data, so excluded from this answer: share_based_compensation.
Covers interest 4.1x even after a 30% EBITDA decline.
| EBITDA decline | Interest coverage |
|---|---|
| 0% | 5.87x |
| 5% | 5.58x |
| 10% | 5.28x |
| 15% | 4.99x |
| 20% | 4.70x |
| 25% | 4.40x |
| 30% | 4.11x |
| 35% | 3.82x |
| 40% | 3.52x |
| 45% | 3.23x |
| 50% | 2.94x |
| 55% | 2.64x |
| 60% | 2.35x |
Balance sheet at 2025-06-30. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
Operating leases are $254,536 of the $254,536 total — a fixed obligation that does not appear in a headline debt figure.
At $0.15, free cash flow must compound -24.13%/yr for 10 years. It has no positive compounding record to compare against.
| Fiscal year | FCF growth | Price requires |
|---|---|---|
| FY2022 | −226.6% | −24.1% |
| FY2024 | −301.9% | −24.1% |
The implied rate of -24.13% has not been achieved in any of the last 2 years.
| Step | Amount | Running total |
|---|---|---|
| Net income | $105,525 | $105,525 |
| Share-based comp | not reported | not reported |
| Other non-cash & working capital | $275,200 | $380,725 |
| Operating cash flow | $380,725 | $380,725 |
| Capex | −$3,880 | $376,845 |
| Free cash flow | $376,845 | $376,845 |
| Fiscal year | Revenue growth | Receivables growth | Gap |
|---|---|---|---|
| FY2020 | -2.4% | -12.2% | -9.9 points |
| FY2021 | 11.4% | -17.6% | -29.0 points |
| FY2022 | 2.2% | 42.5% | 40.3 points |
| FY2023 | 13.8% | 7.3% | -6.5 points |
| FY2024 | -1.6% | 28.4% | 30.1 points |
| FY2025 | 0.5% | -29.3% | -29.8 points |
| Fiscal year | DSO | DIO | DPO | Cash conversion cycle |
|---|---|---|---|---|
| FY2019 | 56.7 days | 137.2 days | 48.7 days | 145.3 days |
| FY2020 | 51 days | 125.3 days | 53.4 days | 122.9 days |
| FY2021 | 37.7 days | 85.6 days | 66.6 days | 56.7 days |
| FY2022 | 52.6 days | 96 days | 60.6 days | 88 days |
| FY2023 | 49.6 days | 86.5 days | 65.7 days | 70.4 days |
| FY2024 | 64.7 days | 86.1 days | 72.5 days | 78.4 days |
| FY2025 | 45.5 days | 119.7 days | 77.5 days | 87.7 days |
| Fiscal year | Accruals / assets |
|---|---|
| FY2019 | 4.3 percent |
| FY2020 | -8.4 percent |
| FY2021 | -15.7 percent |
| FY2022 | 20.6 percent |
| FY2023 | 2.5 percent |
| FY2024 | 10.0 percent |
| FY2025 | -5.5 percent |